Los Angeles, CA and Philadelphia, PA – March 23, 2022 –CancerLife, a digital healthcare company, has completed its randomized control trial which has been sponsored by the John Wayne Cancer Institute, in which it raised quality of life EQ-5 metrics by 14.3%. The company has become the first consumer solution that does not require remote patient monitoring or to be implemented inside a cancer center to drive its quality-of-life outcomes. The ability to scale its consumer app solution to potentially millions of users is now possible.
“Five years ago, we set out on a mission to create a digital health company that could raise quality of life and improve the lives of millions of cancer patients without the need for cancer centers and care teams to implement a complicated workflow disruptive system. Any patient, regardless of location, now can raise their quality of life” said Charles Coltman, Founder and CEO of CancerLife. “We plan to submit these results to the FDA for breakthrough device status as part of our plan to receive reimbursement for our digital behavioral health technology by CMS, Medicaid and other Health Plans.”
CancerLife’s goal is to improve the experience for any cancer patient regardless of where they receive care. By using social behavioral therapy and novel data collection and reporting, CancerLife helps patients change how they think and experience their cancer diagnosis, whilst identifying and lowering the symptom burden. This has a dramatic impact on quality of life, regardless of the care location. The results of the study included 499 participants with a diagnosis of breast cancer who were recruited in over 170 area codes. The results showed a P value of .01 which means the results are 99% certain. No other digital health company has achieved this level of impact.
Validation Institute, an independent 3rd party organization, has validated the study results. Validation Institute’s epidemiology team reviewed the study’s design, data sources, and analysis approach. Validation Institute works with some of the most highly valued digital health companies such as Hinge Health and Virta Health.
“Two armed, randomised trials are rarely done in the digital health industry and CancerLife has raised the bar with these results” stated Benny DiCecca, CEO of Validation Institute. “The analysis clearly demonstrated the impact that the CancerLife solution can have for patients’ lives.”
Cancerlife plans to scale its users and offer its technology to patients as well as work with Employers and Payers to help improve outcomes for this population. Any patient regardless of location can access and use Cancerlife to manage their diagnosis. The company says its vision is to be the number one prescribe digital health solution at the time of a cancer diagnosis. Doctors benefit from recommending Cancerlife to their patients by improving outcomes via higher QoL without the stress of remote patient monitoring. As CMS and Medicaid begin to pay for these apps through the creating of billing codes, Cancerlife is now well positioned within the oncology market.
CancerLife was founded by Charles Coltman, who lost his best friend in 2013 to pancreatic cancer. CancerLife helps patients change how they think and experience their cancer diagnosis, whilst identifying and lowering the symptom burden. This has a dramatic impact on quality of life, regardless of the care location. CancerLife is now live in the app stores. https://cancerlife.com/install
About John Wayne Cancer Institute: John Wayne Cancer Institute is world renounced research center based in Santa Monica, California and part of the Providence Health System which is the third largest health system in the USA.
About Validation Institute:
Validation Institute is an independent, objective, 3rd party organization on a mission to improve the quality and cost of healthcare. Based in Woburn, MA, the organization is made up of a network of health benefits purchasers, health benefits advisors, and healthcare solution providers focused on delivering better health value and stronger outcomes than conventional healthcare. www.validationinstitute.com